Ophtesic (Anhydrous Lidocaine Hydrochloride)

Lidocaine hydrochloride, the active ingredient in Ophtesic, is a local anesthetic presented as a sterile ophthalmic solution for ocular use. It provides temporary loss of sensation on the surface of the eye, facilitating diagnostic and minor surgical procedures.

GNH USA supplies Ophtesic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ophtesic, a lidocaine‑based ophthalmic anesthetic, is employed for procedures involving the ocular surface and anterior segment. - Corneal anesthesia: enables painless examination and removal of corneal foreign bodies. - Intra‑ocular surgery preparation: provides local numbness before cataract or laser procedures. - Conjunctival surgery: facilitates comfortable excision of lesions or biopsies. - Diagnostic testing: allows patient comfort during tonometry or fluorescein staining.

Adverse reactions may occur following ocular administration of lidocaine.

Common Side Effects: - Burning or stinging sensation at the application site. - Temporary blurred vision. - Redness of the conjunctiva. - Mild tearing or lacrimation. - Sensation of foreign body in the eye.

Serious or Rare Side Effects: - Corneal epithelial toxicity or ulceration. - Severe allergic reaction (e.g., angioedema, anaphylaxis). - Persistent intra‑ocular pressure elevation. - Endophthalmitis or intra‑ocular infection. - Vision loss unrelated to the underlying procedure.

When using Ophtesic, consider the following safety measures. - Patient assessment: evaluate for known lidocaine allergy before administration. - Ocular condition: avoid use on compromised corneal epithelium or active infections. - Dosage control: apply only the amount prescribed to limit systemic absorption. - Monitoring: observe for signs of toxicity, especially in pediatric or elderly patients. - Storage: Store at below 25°C: keep in original container, protect from light and moisture.

Lidocaine ophthalmic solutions may interact with certain systemic or topical agents.

Major Interactions (Avoid): - Systemic local anesthetics: concurrent use may increase risk of systemic toxicity. - Monoamine oxidase inhibitors (MAOIs): may potentiate cardiovascular effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor for additive bradycardia if systemic absorption occurs. - Anticholinergic ophthalmic agents: may affect pupil size and intra‑ocular pressure. - CYP450 substrates: lidocaine is metabolized by CYP3A4; monitor levels of drugs with narrow therapeutic windows.